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LETTER TO THE EDITORS
Liver Transplantation for Hepatocellular
Carcinoma with Allografts from Donors after
Circulatory Death: Is the Tumor Recurrence
Genuinely Increased?
Received December 6, 2013; accepted January 9, 2014.
TO THE EDITORS:
We read with interest the article entitled “Inferior Sur-
vival in Liver Transplant Recipients With Hepatocellu-
lar Carcinoma Receiving Donation After Cardiac
Death Liver Allografts” by Croome et al.,1 which was
published in the November 2013 issue of Liver
Transplantation.
The authors analyzed results from the North Ameri-
can Scientific Registry of Transplant Recipients data-
base (collected between January 1995 and October
2011) and observed inferior outcomes for recipients
with hepatocellular carcinoma (HCC) who received
donation after circulatory death (DCD) grafts. Croome
et al.1 hypothesized that more severe ischemia/reper-
fusion injury to DCD grafts might promote HCC
growth and increase HCC relapse rates. Because the
outcomes of the HCC-DCD patient group were inferior
to those of the other patient groups, the authors con-
cluded that this was related to HCC recurrence.
The major flaw of the study, however, is that the
data about tumor recurrence were not collected in the
Scientific Registry of Transplant Recipients database.
In our opinion and in contrast to the authors’ conclu-
sion, we believe that the presented data suggest that
HCC recurrence is not affected by the liver graft type. The
Kaplan-Meier survival estimates provided in Fig. 1 show
an early posttransplant mortality rate for HCC-DCD
recipients as high as 15%, and the remaining deaths
occurred within the first 6 months after transplantation.
This pattern is likely to be related to inferior graft quality
and its related posttransplant complications.2
HCC-related deaths generally occur beyond 12
months.3 In the present study, during further follow-up,
the survival curves for the non-HCC–DCD group, the
HCC–donation after brain death (DBD) group, and the
HCC-DCD group are parallel, and this is confirmed by
data in Table 3. The differences between the 1- and 5-
year survival rates are basically the same for the HCC-
DBD and HCC-DCD groups (20.5% and 20.1%, respec-
tively) despite the significantly higher alpha-fetoprotein
levels in the HCC-DCD group (alpha-fetoprotein lev-
el>400 ng/mL: 12% versus 6%, P 5 0.006).
Patients undergoing transplantation for HCC have
well-preserved liver function and are frequently
matched with extended criteria grafts. The interaction
between HCC and DCD grafts described by the
authors probably reflects this practice rather than dif-
ferent HCC behavior in these livers.
In conclusion, the present study confirms higher
rates of early posttransplant mortality for DCD graft
recipients with HCC. However, we believe that the
data do not prove an increased incidence of HCC
recurrence, and in this respect, the authors’ conclu-
sion should be taken with caution.
Hynek Mergental, M.D., Ph.D.
Firas Zahr Eldeen, M.D.
Paolo Muiesan, M.D., F.R.C.S.
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